Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Patient Guide to Clinical TrialsA Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Complete Title: An Open Label, Multicenter, Dose Escalation, Dose Expansion Phase 1/2 Study with PT217 adapted to include the ChecKpoint inhibitor Atezolizumab as a Phase 2 Study in combination with PT217 in patients with Small Cell Lung Carcinomas and Extrapulmonary Neuroendocrine cancers that are known to be DLL3 expressing cancers
Trial Phase: I/II
Investigator: Ruben Raychaudhuri
This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig (PT217) as a monotherapy and in combination with chemotherapy.
Keywords:
- Neuroendocrine Tumor; Lung Carcinoma, Small-Cell
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Request an Appointment